Mixed results for Erbitux

ImClone (IMCL) and Bristol-Myers (BMY) reported data from a pair of Phase III trials of Erbitux cetuximab to

Read the full 181 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE